Van ECK Associates Corp Raises Position in Pfizer Inc. (NYSE:PFE)

Van ECK Associates Corp lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 33.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,984,150 shares of the biopharmaceutical company's stock after acquiring an additional 3,265,276 shares during the period. Van ECK Associates Corp owned 0.23% of Pfizer worth $373,813,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Trifecta Capital Advisors LLC lifted its position in Pfizer by 3.7% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company's stock valued at $305,000 after acquiring an additional 325 shares during the period. Confluence Wealth Services Inc. boosted its stake in Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company's stock valued at $2,158,000 after purchasing an additional 342 shares during the last quarter. Carr Financial Group Corp increased its holdings in shares of Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company's stock worth $344,000 after purchasing an additional 355 shares in the last quarter. Caldwell Sutter Capital Inc. raised its stake in shares of Pfizer by 0.5% in the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company's stock worth $2,315,000 after purchasing an additional 364 shares during the last quarter. Finally, Bill Few Associates Inc. lifted its holdings in shares of Pfizer by 0.5% during the third quarter. Bill Few Associates Inc. now owns 80,820 shares of the biopharmaceutical company's stock valued at $2,681,000 after purchasing an additional 368 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PFE. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a "buy" rating and a $36.00 target price for the company. Argus cut shares of Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $36.33.

Pfizer Trading Up 1.0 %

PFE traded up $0.25 on Monday, hitting $25.65. The company had a trading volume of 41,630,566 shares, compared to its average volume of 41,999,020. The business's fifty day simple moving average is $26.96 and its 200 day simple moving average is $28.36. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a market cap of $145.24 billion, a PE ratio of 71.03, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company's revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.14 EPS. Equities research analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.55%. Pfizer's dividend payout ratio (DPR) is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.